Full-Time
Operations Finance Senior Manager
Updated on 8/3/2026
Amgen
10,001+ employees
Biotech company creating biologic medicines
No salary listed
Hyderabad, Telangana, India
In Person
 Accounting (2) |
|---|
| , |
Get referred to Amgen
See people who can refer or advise you
- Strong expertise in Operations and Corporate finance, accounting principles, budgeting, forecasting, variance analysis, and strategic financial decision support.
- Experience serving as a finance partner to Operations, Finance, and cross-functional business leaders.
- Experience using financial systems and reporting tools such as SAP, Hyperion, Anaplan, Excel, Smartsheet, S/4HANA, and other standard finance platforms.
- Ability to communicate financial results, risks, opportunities, and recommendations clearly to senior finance leaders and business partners.
- Lead financial planning, budgeting, forecasting, and long-range planning activities for Operations Finance.
- Oversee monthly and quarterly financial reporting, including variance analysis, trend analysis, executive-level commentary, and business performance insights.
- Serve as a strategic finance partner to Operations stakeholders by translating business drivers, cost trends, risks, and opportunities into actionable financial recommendations.
- Manage expense planning, cost center analysis, headcount tracking, capital planning, and other key operational finance activities.
- Analyze actual results versus budget, forecast, and prior periods; identify key variances, explain business drivers, and recommend corrective actions where appropriate.
- Lead the preparation of management presentations, financial summaries, business reviews, and executive decision-support materials.
- Oversee month-end and quarter-end close activities, including accrual review, journal entry support, account reconciliations, and financial validation.
- Ensure financial discipline and compliance with accounting policies, internal controls, and corporate finance requirements.
- Collaborate with Finance, Accounting, Supply Chain, Manufacturing, Procurement, and other business partners to support operational and strategic decision-making.
- Identify, lead, and implement opportunities to improve financial processes, reporting consistency, forecast accuracy, and overall finance effectiveness.
- Lead ad hoc financial analysis, scenario modeling, investment evaluation, and business case development for operational initiatives.
- Leverage financial systems and reporting tools, including SAP, Hyperion, Anaplan, Excel, Smartsheet, S/4HANA, and other standard finance platforms, to drive accurate analysis and reporting.
- Communicate financial results, risks, opportunities, and recommendations clearly to senior finance leaders and business partners.
- Provide coaching, guidance, and review support to finance team members to build analytical capability and ensure high-quality deliverables.
Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.
Company Size
10,001+
Company Stage
IPO
Headquarters
Thousand Oaks, California
Founded
1980
Get referred to Amgen
See people who can refer or advise you
Simplify's Take
What believers are saying
- A broad pipeline targets heart disease, obesity, rare disease, inflammation, and cancer.
- Global reach across roughly 100 countries supports scale and diversification.
- Legacy cash flows from mature biologics fund new medicine development.
What critics are saying
- Enbrel faces pricing pressure after Colorado's 70% price-cap challenge.
- Recent Corlanor and Sensipar recalls expose manufacturing and quality-control weaknesses.
- Biosimilar competition threatens mature biologics and compresses future margins.
What makes Amgen unique
- Amgen combines biologics discovery, manufacturing, and commercialization under one integrated platform.
- Its portfolio spans oncology, cardiovascular, inflammation, bone health, and rare disease.
- Human genetics and biology guide its drug discovery strategy.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Conference Attendance Budget
Company News
Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.
Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.
Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.
Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.
Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.